[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001283226A1 - Methods and compositions for inhibiting rad51 - Google Patents

Methods and compositions for inhibiting rad51

Info

Publication number
AU2001283226A1
AU2001283226A1 AU2001283226A AU2001283226A AU2001283226A1 AU 2001283226 A1 AU2001283226 A1 AU 2001283226A1 AU 2001283226 A AU2001283226 A AU 2001283226A AU 2001283226 A AU2001283226 A AU 2001283226A AU 2001283226 A1 AU2001283226 A1 AU 2001283226A1
Authority
AU
Australia
Prior art keywords
compositions
methods
inhibiting rad51
rad51
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001283226A
Inventor
Gurucharan Reddy
David A. Zarling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pangene Corp
Original Assignee
Pangene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangene Corp filed Critical Pangene Corp
Publication of AU2001283226A1 publication Critical patent/AU2001283226A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001283226A 2001-08-09 2001-08-09 Methods and compositions for inhibiting rad51 Abandoned AU2001283226A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/024986 WO2003013488A2 (en) 2001-08-09 2001-08-09 Methods and compositions for inhibiting rad51

Publications (1)

Publication Number Publication Date
AU2001283226A1 true AU2001283226A1 (en) 2003-02-24

Family

ID=21742766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001283226A Abandoned AU2001283226A1 (en) 2001-08-09 2001-08-09 Methods and compositions for inhibiting rad51

Country Status (2)

Country Link
AU (1) AU2001283226A1 (en)
WO (1) WO2003013488A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10188691B2 (en) 2016-05-27 2019-01-29 Synthex, Inc. Protein interfaces
US11780881B2 (en) 2017-11-22 2023-10-10 Synthex, Inc. Compounds for selective disruption of protein-protein interactions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
CA2909383C (en) 2012-04-12 2020-11-10 University Of Saskatchewan Phthalocyanine compounds useful as reca inhibitors and methods of using same
US10912761B2 (en) 2012-11-30 2021-02-09 The University Of Chicago Methods and compositions involving RAD51 inhibitors
JP2015051946A (en) * 2013-09-06 2015-03-19 学校法人早稲田大学 Compound having cell proliferation inhibitory activity, pharmaceutical composition and screening method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037125A (en) * 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
EP1006185A1 (en) * 1998-10-06 2000-06-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Tissue-specific splice variant of recombination-repair gene rad51b associated with t(12;14)-uterine leiomyomas
US6576759B2 (en) * 1999-02-10 2003-06-10 Pangene Corporation Antisense inhibition of RAD51
EP1204868A1 (en) * 1999-08-10 2002-05-15 Pangene Corporation Cancer treatments and diagnostics utilizing rad51 related molecules and methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10188691B2 (en) 2016-05-27 2019-01-29 Synthex, Inc. Protein interfaces
US11780881B2 (en) 2017-11-22 2023-10-10 Synthex, Inc. Compounds for selective disruption of protein-protein interactions

Also Published As

Publication number Publication date
WO2003013488A2 (en) 2003-02-20
WO2003013488A3 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
AU2002357119A1 (en) Mitocidal compositions and methods
AU2001280968A1 (en) Compositions and methods for directed gene assembly
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
AU2002361623A1 (en) Methods and compositions for chromatography
AU2003256805A1 (en) Compounds compositions and methods
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2002357748A1 (en) Osteopontin-related compositions and methods
AU2002359694A1 (en) Compounds and methods
AU2002361548A1 (en) Compositions and methods for bacteria detection
AU2002337943A1 (en) Novel compositions and methods for cancer
AU2003295574A1 (en) Method and compositions for temporarily incapaciting subjets
AU2002351200A1 (en) Compositions and methods for inhibiting prenyltransferases
AU2001283226A1 (en) Methods and compositions for inhibiting rad51
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AU2002366809A1 (en) Syn3 compositions and methods
AU2002310046A1 (en) Compositions and methods for inhibiting metastasis
AU2003303948A1 (en) Compositions and methods for preventing infection
AU2003275069A1 (en) Compositions and methods for preventing infection
AU2002365136A1 (en) Compositions and methods for controlled release
AU2002359869A1 (en) Pak5-related compositions and methods
AU2002246221A1 (en) Method and composition
AU7597400A (en) Methods and compositions utilizing rad51
AU2002360454A1 (en) Methods and compositions for treating cancer
AU2002345932A1 (en) Compositions and methods for treating atherosclerosis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase